Revance Therapeutics Investor Presentation — March 2020

Document content

Company Presentation

March 2020Forward -Looking Statements / Safe Harbor / Market Data

This presentation contains forward -looking statements, including forward -statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to:

financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical de velopment of our investigational product candidates, including

anticipated near -term milestones; development of a biosimilar to BOTOX®; timing and outcome of regulatory determinations regardi ng potential approval of DAXI and expected PDUFA date and

commercial potential of our drug candidates; anticipated strategic and financial benefits of our distribution agreement with Teo xane; commercial acceptance and potential of our drug product

candidates and our technologies, including with respect to the RHA line of dermal fillers; status of commercial collaboration s, including collaboration agreement with Mylan’s continuation

decision and the timing thereof; demand for our product candidates and drivers of demand; market size, adoption rate and pote ntial revenue; growth opportunities and product pipeline; our

business strategy, timeline and other goals and market for our anticipated products, plans and prospects, including our pre -comm ercialization plans; our ability to leverage our investment in our

development and manufacturing platform; and our commercial and intellectual property strategy.

Forward -looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not

limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical de velopment process, including the risk that clinical trials may not have an

effective design or generate positive results, or that positive results would assure regulatory approval or commercial succes s of our product candidates, including our ability to receive timely

approval of DAXI; that we may not obtain the anticipated financial and other benefits of the collaboration agreement with Myl an or distribution agreement with Teoxane, including our ability to

realize anticipated synergies and successfully commercialize Teoxane’s dermal fillers; our ability to obtain and maintain reg ulatory approval of our product candidates; our ability to obtain

funding for our operations; our plans to research, develop and commercialize our product candidates; our ability to achieve m arket acceptance of our product candidates; unanticipated costs or

delays in research, development and commercialization efforts; the size and growth potential of the markets for our product c and idates; our ability to effectively and reliably manufacture supplies